Global Virus like Particle (VLP) Vaccines Market Growth 2026-2032
The global Virus like Particle (VLP) Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo. While they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another essential advantage of VLPs is that they more effectively activate critical aspects of the immune response to achieve potent immune stimulation and provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are currently used for several diseases.
United States market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Virus like Particle (VLP) Vaccines players cover AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Virus like Particle (VLP) Vaccines Industry Forecast? looks at past sales and reviews total world Virus like Particle (VLP) Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Virus like Particle (VLP) Vaccines sales for 2026 through 2032. With Virus like Particle (VLP) Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Virus like Particle (VLP) Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Virus like Particle (VLP) Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Virus like Particle (VLP) Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Virus like Particle (VLP) Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Virus like Particle (VLP) Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Virus like Particle (VLP) Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Virus like Particle (VLP) Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Virus like Particle (VLP) Vaccines market?
What factors are driving Virus like Particle (VLP) Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Virus like Particle (VLP) Vaccines market opportunities vary by end market size?
How does Virus like Particle (VLP) Vaccines break out by Type, by Application?
Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo. While they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another essential advantage of VLPs is that they more effectively activate critical aspects of the immune response to achieve potent immune stimulation and provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are currently used for several diseases.
United States market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Virus like Particle (VLP) Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Virus like Particle (VLP) Vaccines players cover AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Virus like Particle (VLP) Vaccines Industry Forecast? looks at past sales and reviews total world Virus like Particle (VLP) Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Virus like Particle (VLP) Vaccines sales for 2026 through 2032. With Virus like Particle (VLP) Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Virus like Particle (VLP) Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Virus like Particle (VLP) Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Virus like Particle (VLP) Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Virus like Particle (VLP) Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Virus like Particle (VLP) Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Virus like Particle (VLP) Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Virus like Particle (VLP) Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Prophylactic Vaccine
- Therapeutic Vaccine
- Hepatitis B Virus (HBV)
- Human Papillomavirus (HPV)
- Hepatitis E Virus (HEV)
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca Group (Icosavax)
- Premas Biotech
- BioAgilytix
- Coriolis
- Charles River Laboratories
- VBI Vaccines Inc
- Creative Biostructure
- WuXi Biologics
- Creative Diagnostics
- Shanghai Bovax Biotechnology Co., Ltd.
- Junshi Biosciences
- Luye Pharma Group
- Chengdu Kanghua Biological Products Co., Ltd.
What is the 10-year outlook for the global Virus like Particle (VLP) Vaccines market?
What factors are driving Virus like Particle (VLP) Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Virus like Particle (VLP) Vaccines market opportunities vary by end market size?
How does Virus like Particle (VLP) Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Virus like Particle (VLP) Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Virus like Particle (VLP) Vaccines by Country/Region, 2021, 2025 & 2032
2.2 Virus like Particle (VLP) Vaccines Segment by Type
2.2.1 Prophylactic Vaccine
2.2.2 Therapeutic Vaccine
2.2.3 Virus like Particle (VLP) Vaccines Sales by Type
2.2.3.1 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
2.2.3.2 Global Virus like Particle (VLP) Vaccines Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Virus like Particle (VLP) Vaccines Sale Price by Type (2021-2026)
2.3 Virus like Particle (VLP) Vaccines Segment by Application
2.3.1 Hepatitis B Virus (HBV)
2.3.2 Human Papillomavirus (HPV)
2.3.3 Hepatitis E Virus (HEV)
2.3.4 Other
2.3.5 Virus like Particle (VLP) Vaccines Sales by Application
2.3.5.1 Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2021-2026)
2.3.5.2 Global Virus like Particle (VLP) Vaccines Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Virus like Particle (VLP) Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Virus like Particle (VLP) Vaccines Breakdown Data by Company
3.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global Virus like Particle (VLP) Vaccines Sales Market Share by Company (2021-2026)
3.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Company (2021-2026)
3.2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global Virus like Particle (VLP) Vaccines Sale Price by Company
3.4 Key Manufacturers Virus like Particle (VLP) Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Virus like Particle (VLP) Vaccines Product Location Distribution
3.4.2 Players Virus like Particle (VLP) Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRUS LIKE PARTICLE (VLP) VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Virus like Particle (VLP) Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Virus like Particle (VLP) Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas Virus like Particle (VLP) Vaccines Sales Growth
4.4 APAC Virus like Particle (VLP) Vaccines Sales Growth
4.5 Europe Virus like Particle (VLP) Vaccines Sales Growth
4.6 Middle East & Africa Virus like Particle (VLP) Vaccines Sales Growth
5 AMERICAS
5.1 Americas Virus like Particle (VLP) Vaccines Sales by Country
5.1.1 Americas Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
5.1.2 Americas Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
5.2 Americas Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
5.3 Americas Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Virus like Particle (VLP) Vaccines Sales by Region
6.1.1 APAC Virus like Particle (VLP) Vaccines Sales by Region (2021-2026)
6.1.2 APAC Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026)
6.2 APAC Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
6.3 APAC Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Virus like Particle (VLP) Vaccines by Country
7.1.1 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
7.1.2 Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
7.2 Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
7.3 Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Virus like Particle (VLP) Vaccines by Country
8.1.1 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Virus like Particle (VLP) Vaccines
10.3 Manufacturing Process Analysis of Virus like Particle (VLP) Vaccines
10.4 Industry Chain Structure of Virus like Particle (VLP) Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Virus like Particle (VLP) Vaccines Distributors
11.3 Virus like Particle (VLP) Vaccines Customer
12 WORLD FORECAST REVIEW FOR VIRUS LIKE PARTICLE (VLP) VACCINES BY GEOGRAPHIC REGION
12.1 Global Virus like Particle (VLP) Vaccines Market Size Forecast by Region
12.1.1 Global Virus like Particle (VLP) Vaccines Forecast by Region (2027-2032)
12.1.2 Global Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Virus like Particle (VLP) Vaccines Forecast by Type (2027-2032)
12.7 Global Virus like Particle (VLP) Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Group (Icosavax)
13.1.1 AstraZeneca Group (Icosavax) Company Information
13.1.2 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.1.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Group (Icosavax) Main Business Overview
13.1.5 AstraZeneca Group (Icosavax) Latest Developments
13.2 Premas Biotech
13.2.1 Premas Biotech Company Information
13.2.2 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.2.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Premas Biotech Main Business Overview
13.2.5 Premas Biotech Latest Developments
13.3 BioAgilytix
13.3.1 BioAgilytix Company Information
13.3.2 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.3.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BioAgilytix Main Business Overview
13.3.5 BioAgilytix Latest Developments
13.4 Coriolis
13.4.1 Coriolis Company Information
13.4.2 Coriolis Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.4.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Coriolis Main Business Overview
13.4.5 Coriolis Latest Developments
13.5 Charles River Laboratories
13.5.1 Charles River Laboratories Company Information
13.5.2 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.5.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Charles River Laboratories Main Business Overview
13.5.5 Charles River Laboratories Latest Developments
13.6 VBI Vaccines Inc
13.6.1 VBI Vaccines Inc Company Information
13.6.2 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 VBI Vaccines Inc Main Business Overview
13.6.5 VBI Vaccines Inc Latest Developments
13.7 Creative Biostructure
13.7.1 Creative Biostructure Company Information
13.7.2 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.7.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative Biostructure Main Business Overview
13.7.5 Creative Biostructure Latest Developments
13.8 WuXi Biologics
13.8.1 WuXi Biologics Company Information
13.8.2 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.8.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 WuXi Biologics Main Business Overview
13.8.5 WuXi Biologics Latest Developments
13.9 Creative Diagnostics
13.9.1 Creative Diagnostics Company Information
13.9.2 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.9.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Creative Diagnostics Main Business Overview
13.9.5 Creative Diagnostics Latest Developments
13.10 Shanghai Bovax Biotechnology Co., Ltd.
13.10.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
13.10.2 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.10.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Shanghai Bovax Biotechnology Co., Ltd. Main Business Overview
13.10.5 Shanghai Bovax Biotechnology Co., Ltd. Latest Developments
13.11 Junshi Biosciences
13.11.1 Junshi Biosciences Company Information
13.11.2 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.11.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Junshi Biosciences Main Business Overview
13.11.5 Junshi Biosciences Latest Developments
13.12 Luye Pharma Group
13.12.1 Luye Pharma Group Company Information
13.12.2 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.12.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Luye Pharma Group Main Business Overview
13.12.5 Luye Pharma Group Latest Developments
13.13 Chengdu Kanghua Biological Products Co., Ltd.
13.13.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.13.2 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.13.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.13.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Virus like Particle (VLP) Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Virus like Particle (VLP) Vaccines by Country/Region, 2021, 2025 & 2032
2.2 Virus like Particle (VLP) Vaccines Segment by Type
2.2.1 Prophylactic Vaccine
2.2.2 Therapeutic Vaccine
2.2.3 Virus like Particle (VLP) Vaccines Sales by Type
2.2.3.1 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
2.2.3.2 Global Virus like Particle (VLP) Vaccines Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Virus like Particle (VLP) Vaccines Sale Price by Type (2021-2026)
2.3 Virus like Particle (VLP) Vaccines Segment by Application
2.3.1 Hepatitis B Virus (HBV)
2.3.2 Human Papillomavirus (HPV)
2.3.3 Hepatitis E Virus (HEV)
2.3.4 Other
2.3.5 Virus like Particle (VLP) Vaccines Sales by Application
2.3.5.1 Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2021-2026)
2.3.5.2 Global Virus like Particle (VLP) Vaccines Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Virus like Particle (VLP) Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Virus like Particle (VLP) Vaccines Breakdown Data by Company
3.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global Virus like Particle (VLP) Vaccines Sales Market Share by Company (2021-2026)
3.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Company (2021-2026)
3.2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global Virus like Particle (VLP) Vaccines Sale Price by Company
3.4 Key Manufacturers Virus like Particle (VLP) Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Virus like Particle (VLP) Vaccines Product Location Distribution
3.4.2 Players Virus like Particle (VLP) Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRUS LIKE PARTICLE (VLP) VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Virus like Particle (VLP) Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Virus like Particle (VLP) Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global Virus like Particle (VLP) Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global Virus like Particle (VLP) Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas Virus like Particle (VLP) Vaccines Sales Growth
4.4 APAC Virus like Particle (VLP) Vaccines Sales Growth
4.5 Europe Virus like Particle (VLP) Vaccines Sales Growth
4.6 Middle East & Africa Virus like Particle (VLP) Vaccines Sales Growth
5 AMERICAS
5.1 Americas Virus like Particle (VLP) Vaccines Sales by Country
5.1.1 Americas Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
5.1.2 Americas Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
5.2 Americas Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
5.3 Americas Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Virus like Particle (VLP) Vaccines Sales by Region
6.1.1 APAC Virus like Particle (VLP) Vaccines Sales by Region (2021-2026)
6.1.2 APAC Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026)
6.2 APAC Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
6.3 APAC Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Virus like Particle (VLP) Vaccines by Country
7.1.1 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
7.1.2 Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
7.2 Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
7.3 Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Virus like Particle (VLP) Vaccines by Country
8.1.1 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Virus like Particle (VLP) Vaccines
10.3 Manufacturing Process Analysis of Virus like Particle (VLP) Vaccines
10.4 Industry Chain Structure of Virus like Particle (VLP) Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Virus like Particle (VLP) Vaccines Distributors
11.3 Virus like Particle (VLP) Vaccines Customer
12 WORLD FORECAST REVIEW FOR VIRUS LIKE PARTICLE (VLP) VACCINES BY GEOGRAPHIC REGION
12.1 Global Virus like Particle (VLP) Vaccines Market Size Forecast by Region
12.1.1 Global Virus like Particle (VLP) Vaccines Forecast by Region (2027-2032)
12.1.2 Global Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Virus like Particle (VLP) Vaccines Forecast by Type (2027-2032)
12.7 Global Virus like Particle (VLP) Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Group (Icosavax)
13.1.1 AstraZeneca Group (Icosavax) Company Information
13.1.2 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.1.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Group (Icosavax) Main Business Overview
13.1.5 AstraZeneca Group (Icosavax) Latest Developments
13.2 Premas Biotech
13.2.1 Premas Biotech Company Information
13.2.2 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.2.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Premas Biotech Main Business Overview
13.2.5 Premas Biotech Latest Developments
13.3 BioAgilytix
13.3.1 BioAgilytix Company Information
13.3.2 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.3.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BioAgilytix Main Business Overview
13.3.5 BioAgilytix Latest Developments
13.4 Coriolis
13.4.1 Coriolis Company Information
13.4.2 Coriolis Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.4.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Coriolis Main Business Overview
13.4.5 Coriolis Latest Developments
13.5 Charles River Laboratories
13.5.1 Charles River Laboratories Company Information
13.5.2 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.5.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Charles River Laboratories Main Business Overview
13.5.5 Charles River Laboratories Latest Developments
13.6 VBI Vaccines Inc
13.6.1 VBI Vaccines Inc Company Information
13.6.2 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 VBI Vaccines Inc Main Business Overview
13.6.5 VBI Vaccines Inc Latest Developments
13.7 Creative Biostructure
13.7.1 Creative Biostructure Company Information
13.7.2 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.7.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative Biostructure Main Business Overview
13.7.5 Creative Biostructure Latest Developments
13.8 WuXi Biologics
13.8.1 WuXi Biologics Company Information
13.8.2 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.8.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 WuXi Biologics Main Business Overview
13.8.5 WuXi Biologics Latest Developments
13.9 Creative Diagnostics
13.9.1 Creative Diagnostics Company Information
13.9.2 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.9.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Creative Diagnostics Main Business Overview
13.9.5 Creative Diagnostics Latest Developments
13.10 Shanghai Bovax Biotechnology Co., Ltd.
13.10.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
13.10.2 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.10.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Shanghai Bovax Biotechnology Co., Ltd. Main Business Overview
13.10.5 Shanghai Bovax Biotechnology Co., Ltd. Latest Developments
13.11 Junshi Biosciences
13.11.1 Junshi Biosciences Company Information
13.11.2 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.11.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Junshi Biosciences Main Business Overview
13.11.5 Junshi Biosciences Latest Developments
13.12 Luye Pharma Group
13.12.1 Luye Pharma Group Company Information
13.12.2 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.12.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Luye Pharma Group Main Business Overview
13.12.5 Luye Pharma Group Latest Developments
13.13 Chengdu Kanghua Biological Products Co., Ltd.
13.13.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.13.2 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
13.13.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.13.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Virus like Particle (VLP) Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Virus like Particle (VLP) Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Prophylactic Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 6. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Table 7. Global Virus like Particle (VLP) Vaccines Revenue by Type (2021-2026) & ($ million)
Table 8. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2026)
Table 9. Global Virus like Particle (VLP) Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Global Virus like Particle (VLP) Vaccines Sale by Application (2021-2026) & (K Dose)
Table 11. Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2021-2026)
Table 12. Global Virus like Particle (VLP) Vaccines Revenue by Application (2021-2026) & ($ million)
Table 13. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2026)
Table 14. Global Virus like Particle (VLP) Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 15. Global Virus like Particle (VLP) Vaccines Sales by Company (2021-2026) & (K Dose)
Table 16. Global Virus like Particle (VLP) Vaccines Sales Market Share by Company (2021-2026)
Table 17. Global Virus like Particle (VLP) Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company (2021-2026)
Table 19. Global Virus like Particle (VLP) Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 20. Key Manufacturers Virus like Particle (VLP) Vaccines Producing Area Distribution and Sales Area
Table 21. Players Virus like Particle (VLP) Vaccines Products Offered
Table 22. Virus like Particle (VLP) Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Virus like Particle (VLP) Vaccines Sales by Geographic Region (2021-2026) & (K Dose)
Table 26. Global Virus like Particle (VLP) Vaccines Sales Market Share Geographic Region (2021-2026)
Table 27. Global Virus like Particle (VLP) Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Virus like Particle (VLP) Vaccines Sales by Country/Region (2021-2026) & (K Dose)
Table 30. Global Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2021-2026)
Table 31. Global Virus like Particle (VLP) Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 34. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026)
Table 35. Americas Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 37. Americas Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 38. APAC Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (K Dose)
Table 39. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021-2026)
Table 40. APAC Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 42. APAC Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 43. Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 44. Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 46. Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 47. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 48. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 50. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Virus like Particle (VLP) Vaccines
Table 52. Key Market Challenges & Risks of Virus like Particle (VLP) Vaccines
Table 53. Key Industry Trends of Virus like Particle (VLP) Vaccines
Table 54. Virus like Particle (VLP) Vaccines Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Virus like Particle (VLP) Vaccines Distributors List
Table 57. Virus like Particle (VLP) Vaccines Customer List
Table 58. Global Virus like Particle (VLP) Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 59. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 61. Americas Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Virus like Particle (VLP) Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 63. APAC Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 65. Europe Virus like Particle (VLP) Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 67. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Virus like Particle (VLP) Vaccines Sales Forecast by Type (2027-2032) & (K Dose)
Table 69. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Virus like Particle (VLP) Vaccines Sales Forecast by Application (2027-2032) & (K Dose)
Table 71. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. AstraZeneca Group (Icosavax) Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 73. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 74. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 75. AstraZeneca Group (Icosavax) Main Business
Table 76. AstraZeneca Group (Icosavax) Latest Developments
Table 77. Premas Biotech Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 78. Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 79. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 80. Premas Biotech Main Business
Table 81. Premas Biotech Latest Developments
Table 82. BioAgilytix Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 83. BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 84. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 85. BioAgilytix Main Business
Table 86. BioAgilytix Latest Developments
Table 87. Coriolis Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 88. Coriolis Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 89. Coriolis Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Coriolis Main Business
Table 91. Coriolis Latest Developments
Table 92. Charles River Laboratories Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 93. Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 94. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. Charles River Laboratories Main Business
Table 96. Charles River Laboratories Latest Developments
Table 97. VBI Vaccines Inc Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 98. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 99. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. VBI Vaccines Inc Main Business
Table 101. VBI Vaccines Inc Latest Developments
Table 102. Creative Biostructure Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 103. Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 104. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Creative Biostructure Main Business
Table 106. Creative Biostructure Latest Developments
Table 107. WuXi Biologics Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 108. WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 109. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. WuXi Biologics Main Business
Table 111. WuXi Biologics Latest Developments
Table 112. Creative Diagnostics Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 113. Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 114. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. Creative Diagnostics Main Business
Table 116. Creative Diagnostics Latest Developments
Table 117. Shanghai Bovax Biotechnology Co., Ltd. Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 118. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 119. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Shanghai Bovax Biotechnology Co., Ltd. Main Business
Table 121. Shanghai Bovax Biotechnology Co., Ltd. Latest Developments
Table 122. Junshi Biosciences Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 123. Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 124. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Junshi Biosciences Main Business
Table 126. Junshi Biosciences Latest Developments
Table 127. Luye Pharma Group Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 128. Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 129. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Luye Pharma Group Main Business
Table 131. Luye Pharma Group Latest Developments
Table 132. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 134. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 135. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 136. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 1. Virus like Particle (VLP) Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Virus like Particle (VLP) Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Prophylactic Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 6. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Table 7. Global Virus like Particle (VLP) Vaccines Revenue by Type (2021-2026) & ($ million)
Table 8. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2026)
Table 9. Global Virus like Particle (VLP) Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Global Virus like Particle (VLP) Vaccines Sale by Application (2021-2026) & (K Dose)
Table 11. Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2021-2026)
Table 12. Global Virus like Particle (VLP) Vaccines Revenue by Application (2021-2026) & ($ million)
Table 13. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2026)
Table 14. Global Virus like Particle (VLP) Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 15. Global Virus like Particle (VLP) Vaccines Sales by Company (2021-2026) & (K Dose)
Table 16. Global Virus like Particle (VLP) Vaccines Sales Market Share by Company (2021-2026)
Table 17. Global Virus like Particle (VLP) Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company (2021-2026)
Table 19. Global Virus like Particle (VLP) Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 20. Key Manufacturers Virus like Particle (VLP) Vaccines Producing Area Distribution and Sales Area
Table 21. Players Virus like Particle (VLP) Vaccines Products Offered
Table 22. Virus like Particle (VLP) Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Virus like Particle (VLP) Vaccines Sales by Geographic Region (2021-2026) & (K Dose)
Table 26. Global Virus like Particle (VLP) Vaccines Sales Market Share Geographic Region (2021-2026)
Table 27. Global Virus like Particle (VLP) Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Virus like Particle (VLP) Vaccines Sales by Country/Region (2021-2026) & (K Dose)
Table 30. Global Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2021-2026)
Table 31. Global Virus like Particle (VLP) Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 34. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026)
Table 35. Americas Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 37. Americas Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 38. APAC Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (K Dose)
Table 39. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021-2026)
Table 40. APAC Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 42. APAC Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 43. Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 44. Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 46. Europe Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 47. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Dose)
Table 48. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Dose)
Table 50. Middle East & Africa Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Virus like Particle (VLP) Vaccines
Table 52. Key Market Challenges & Risks of Virus like Particle (VLP) Vaccines
Table 53. Key Industry Trends of Virus like Particle (VLP) Vaccines
Table 54. Virus like Particle (VLP) Vaccines Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Virus like Particle (VLP) Vaccines Distributors List
Table 57. Virus like Particle (VLP) Vaccines Customer List
Table 58. Global Virus like Particle (VLP) Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 59. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 61. Americas Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Virus like Particle (VLP) Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 63. APAC Virus like Particle (VLP) Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 65. Europe Virus like Particle (VLP) Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 67. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Virus like Particle (VLP) Vaccines Sales Forecast by Type (2027-2032) & (K Dose)
Table 69. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Virus like Particle (VLP) Vaccines Sales Forecast by Application (2027-2032) & (K Dose)
Table 71. Global Virus like Particle (VLP) Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. AstraZeneca Group (Icosavax) Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 73. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 74. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 75. AstraZeneca Group (Icosavax) Main Business
Table 76. AstraZeneca Group (Icosavax) Latest Developments
Table 77. Premas Biotech Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 78. Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 79. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 80. Premas Biotech Main Business
Table 81. Premas Biotech Latest Developments
Table 82. BioAgilytix Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 83. BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 84. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 85. BioAgilytix Main Business
Table 86. BioAgilytix Latest Developments
Table 87. Coriolis Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 88. Coriolis Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 89. Coriolis Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Coriolis Main Business
Table 91. Coriolis Latest Developments
Table 92. Charles River Laboratories Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 93. Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 94. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. Charles River Laboratories Main Business
Table 96. Charles River Laboratories Latest Developments
Table 97. VBI Vaccines Inc Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 98. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 99. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. VBI Vaccines Inc Main Business
Table 101. VBI Vaccines Inc Latest Developments
Table 102. Creative Biostructure Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 103. Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 104. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Creative Biostructure Main Business
Table 106. Creative Biostructure Latest Developments
Table 107. WuXi Biologics Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 108. WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 109. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. WuXi Biologics Main Business
Table 111. WuXi Biologics Latest Developments
Table 112. Creative Diagnostics Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 113. Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 114. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. Creative Diagnostics Main Business
Table 116. Creative Diagnostics Latest Developments
Table 117. Shanghai Bovax Biotechnology Co., Ltd. Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 118. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 119. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Shanghai Bovax Biotechnology Co., Ltd. Main Business
Table 121. Shanghai Bovax Biotechnology Co., Ltd. Latest Developments
Table 122. Junshi Biosciences Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 123. Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 124. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Junshi Biosciences Main Business
Table 126. Junshi Biosciences Latest Developments
Table 127. Luye Pharma Group Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 128. Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 129. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Luye Pharma Group Main Business
Table 131. Luye Pharma Group Latest Developments
Table 132. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Virus like Particle (VLP) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolios and Specifications
Table 134. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 135. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 136. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Virus like Particle (VLP) Vaccines
Figure 2. Virus like Particle (VLP) Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Virus like Particle (VLP) Vaccines Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Virus like Particle (VLP) Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Virus like Particle (VLP) Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2025)
Figure 10. Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Prophylactic Vaccine
Figure 12. Product Picture of Therapeutic Vaccine
Figure 13. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type in 2026
Figure 14. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2026)
Figure 15. Virus like Particle (VLP) Vaccines Consumed in Hepatitis B Virus (HBV)
Figure 16. Global Virus like Particle (VLP) Vaccines Market: Hepatitis B Virus (HBV) (2021-2026) & (K Dose)
Figure 17. Virus like Particle (VLP) Vaccines Consumed in Human Papillomavirus (HPV)
Figure 18. Global Virus like Particle (VLP) Vaccines Market: Human Papillomavirus (HPV) (2021-2026) & (K Dose)
Figure 19. Virus like Particle (VLP) Vaccines Consumed in Hepatitis E Virus (HEV)
Figure 20. Global Virus like Particle (VLP) Vaccines Market: Hepatitis E Virus (HEV) (2021-2026) & (K Dose)
Figure 21. Virus like Particle (VLP) Vaccines Consumed in Other
Figure 22. Global Virus like Particle (VLP) Vaccines Market: Other (2021-2026) & (K Dose)
Figure 23. Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2025)
Figure 24. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application in 2026
Figure 25. Virus like Particle (VLP) Vaccines Sales by Company in 2026 (K Dose)
Figure 26. Global Virus like Particle (VLP) Vaccines Sales Market Share by Company in 2026
Figure 27. Virus like Particle (VLP) Vaccines Revenue by Company in 2026 ($ millions)
Figure 28. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company in 2026
Figure 29. Global Virus like Particle (VLP) Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 32. Americas Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 33. APAC Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 34. APAC Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 35. Europe Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 36. Europe Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 38. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 39. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Country in 2026
Figure 40. Americas Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Figure 41. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 42. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 43. United States Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Region in 2026
Figure 48. APAC Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021-2026)
Figure 49. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 50. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 51. China Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 55. India Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country in 2026
Figure 59. Europe Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Figure 60. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 61. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 62. Germany Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. France Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 70. Egypt Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Virus like Particle (VLP) Vaccines in 2026
Figure 76. Manufacturing Process Analysis of Virus like Particle (VLP) Vaccines
Figure 77. Industry Chain Structure of Virus like Particle (VLP) Vaccines
Figure 78. Channels of Distribution
Figure 79. Global Virus like Particle (VLP) Vaccines Sales Market Forecast by Region (2027-2032)
Figure 80. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Virus like Particle (VLP) Vaccines
Figure 2. Virus like Particle (VLP) Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Virus like Particle (VLP) Vaccines Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Virus like Particle (VLP) Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Virus like Particle (VLP) Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2025)
Figure 10. Virus like Particle (VLP) Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Prophylactic Vaccine
Figure 12. Product Picture of Therapeutic Vaccine
Figure 13. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type in 2026
Figure 14. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2026)
Figure 15. Virus like Particle (VLP) Vaccines Consumed in Hepatitis B Virus (HBV)
Figure 16. Global Virus like Particle (VLP) Vaccines Market: Hepatitis B Virus (HBV) (2021-2026) & (K Dose)
Figure 17. Virus like Particle (VLP) Vaccines Consumed in Human Papillomavirus (HPV)
Figure 18. Global Virus like Particle (VLP) Vaccines Market: Human Papillomavirus (HPV) (2021-2026) & (K Dose)
Figure 19. Virus like Particle (VLP) Vaccines Consumed in Hepatitis E Virus (HEV)
Figure 20. Global Virus like Particle (VLP) Vaccines Market: Hepatitis E Virus (HEV) (2021-2026) & (K Dose)
Figure 21. Virus like Particle (VLP) Vaccines Consumed in Other
Figure 22. Global Virus like Particle (VLP) Vaccines Market: Other (2021-2026) & (K Dose)
Figure 23. Global Virus like Particle (VLP) Vaccines Sale Market Share by Application (2025)
Figure 24. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application in 2026
Figure 25. Virus like Particle (VLP) Vaccines Sales by Company in 2026 (K Dose)
Figure 26. Global Virus like Particle (VLP) Vaccines Sales Market Share by Company in 2026
Figure 27. Virus like Particle (VLP) Vaccines Revenue by Company in 2026 ($ millions)
Figure 28. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Company in 2026
Figure 29. Global Virus like Particle (VLP) Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 32. Americas Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 33. APAC Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 34. APAC Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 35. Europe Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 36. Europe Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Virus like Particle (VLP) Vaccines Sales 2021-2026 (K Dose)
Figure 38. Middle East & Africa Virus like Particle (VLP) Vaccines Revenue 2021-2026 ($ millions)
Figure 39. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Country in 2026
Figure 40. Americas Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Figure 41. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 42. Americas Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 43. United States Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Region in 2026
Figure 48. APAC Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021-2026)
Figure 49. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 50. APAC Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 51. China Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 55. India Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country in 2026
Figure 59. Europe Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021-2026)
Figure 60. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 61. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 62. Germany Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. France Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026)
Figure 70. Egypt Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Virus like Particle (VLP) Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Virus like Particle (VLP) Vaccines in 2026
Figure 76. Manufacturing Process Analysis of Virus like Particle (VLP) Vaccines
Figure 77. Industry Chain Structure of Virus like Particle (VLP) Vaccines
Figure 78. Channels of Distribution
Figure 79. Global Virus like Particle (VLP) Vaccines Sales Market Forecast by Region (2027-2032)
Figure 80. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Virus like Particle (VLP) Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Virus like Particle (VLP) Vaccines Revenue Market Share Forecast by Application (2027-2032)
